Botulinum neurotoxin type A (BoNT-A) is used across coexisting craniocervical conditions, and therapeutic response is often overinterpreted as evidence of a shared generator. The bruxism literature shows why. Across six controlled studies with event-level outcome measurement, reported effects on event frequency track not dose or injection field but whether the rule used to detect an event could follow the amplitude...
✦ The floor
Discussion
Signed responses from readers of the wire.
No actionable change for audiology practice; the paper is a cautionary methodological analysis for researchers and clinicians interpreting Botox treatment responses in craniocervical comorbidities.
Craniocervical comorbidities including tinnitus and vestibular disorders frequently co-occur, and misinterpreting shared treatment responses as evidence of a unified cause could lead to flawed diagnostic reasoning in audiology and related fields.
- 01Botulinum toxin type A (Botox) is used across multiple coexisting head-and-neck conditions.
- 02Symptom relief from Botox across comorbid conditions does not confirm a shared pathological mechanism.
- 03The paper cautions against reverse-inference reasoning in interpreting therapeutic responses.
- 04Conditions analyzed include craniocervical disorders that overlap with audiology presentations (e.g., tinnitus, TMJ).
- 05Findings are methodological and analytical, not based on a new clinical trial.
A therapeutic response to botulinum toxin across multiple craniocervical conditions should not be interpreted as evidence of a shared pathological generator.
opinionpartially supported- PMID
- 42784282
- DOI
- 10.3390/toxins18090358.
- Journal
- Toxins
- Publication type
- review
- Evidence level
- 5
- Population
- Patients with coexisting craniocervical conditions treated with botulinum neurotoxin type A
- Intervention
- Botulinum neurotoxin type A (BoNT-A)
Primary outcomes
Interpretation of therapeutic response across craniocervical comorbidities; Validity of shared pathological generator hypothesis